FDA clears GE's Clariscan macrocyclic GBCA

By AuntMinnie.com staff writers

November 4, 2019 -- GE Healthcare has received U.S. Food and Drug Administration (FDA) clearance for use of the company's Clariscan macrocyclic gadolinium-based contrast agent (GBCA) with MRI scans.

Previously introduced at ECR 2017 in Vienna, the Clariscan contrast agent is designed to improve visualization of the blood-brain barrier and vascular abnormalities in the brain, spine, and related tissues of adult and pediatric patients.

GE has received approval for Clariscan in more than 55 countries, the company said.

Copyright © 2019 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking